| Title |
Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, May 2017
|
| DOI | 10.1007/s10549-017-4308-3 |
| Pubmed ID | |
| Authors |
Chiaming Fan, Kristen R. Georgiou, Howard A. Morris, Ross A. McKinnon, Dorothy M. K. Keefe, Peter R. Howe, Cory J. Xian |
| Abstract |
Anthracyclines (including doxorubicin) are still the backbone of commonly used breast cancer chemotherapy regimens. Despite increasing use of doxorubicin and cyclophosphamide (AC) combinations for treating breast cancer, their potential to cause adverse skeletal effects remains unclear. This study examined the effects of treatments with the AC regimen on bone and bone marrow in adult female rats. AC treatment for four cycles (weekly intravenous injection of 2 mg/kg doxorubicin and 20 mg/kg cyclophosphamide) resulted in a reduced volume of trabecular bone at the metaphysis, which was associated with reduced serum levels of 25-hydroxy vitamin D3 and alkaline phosphatase. Reductions in densities of osteocytes and bone lining cells were also observed. In addition, bone marrow was severely damaged, including a severe reduction in bone marrow cellularity and an increase in marrow adipocyte content. Accompanying these changes, there were increases in mRNA expression of adipogenesis regulatory genes (PPARγ and FABP4) and an inflammatory cytokine (TNFα) in metaphysis bone and bone marrow. This study indicates that AC chemotherapy may induce some bone loss, due to reduced bone formation, and bone marrow damage, due to increased marrow adiposity. Preventive strategies for preserving the bone and bone marrow microenvironment during anthracycline chemotherapy warrant further investigation. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Slovenia | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 9 | 18% |
| Researcher | 3 | 6% |
| Student > Postgraduate | 3 | 6% |
| Student > Doctoral Student | 3 | 6% |
| Professor | 3 | 6% |
| Other | 12 | 24% |
| Unknown | 16 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 14% |
| Biochemistry, Genetics and Molecular Biology | 6 | 12% |
| Agricultural and Biological Sciences | 5 | 10% |
| Engineering | 5 | 10% |
| Nursing and Health Professions | 3 | 6% |
| Other | 6 | 12% |
| Unknown | 17 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 October 2017.
All research outputs
#14,939,304
of 22,977,819 outputs
Outputs from Breast Cancer Research and Treatment
#3,212
of 4,675 outputs
Outputs of similar age
#186,631
of 313,455 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#54
of 98 outputs
Altmetric has tracked 22,977,819 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,675 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 313,455 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.